← Leaderboards
Dihua Yu
University Of Tx Md Anderson Can Ctr
$18,443,603
Attributed
$18,651,874
Total exposure
14
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$18,651,874 · 14
By mechanism
R01$14,954,325 · 8
P30$1,610,676 · 2
P01$842,087 · 1
R21$794,122 · 2
P50$450,664 · 1
Top collaborators
- Yi Xiao2 shared
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- Ronald Anthony Depinho$97,148,322
- Scott Kopetz$13,199,822
- Anil K Sood$29,572,737
- Marina Y Konopleva$11,210,192
- Cassian Yee$17,221,393
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsNeoplasm MetastasisMalignant Breast NeoplasmMalignant NeoplasmsTumorTumor ProgressionMediatingRecurrenceCancer CellIn VivoSignal TransductionMammary NeoplasmsOverexpressionPlayPathway InteractionsMouse ModelTherapeutic TargetTranslatingBiologicalWomanClinical TrialsEventGrowthPrevent
Grant awards (65)
Exploring the Function of MHC-II/Lag3 Axis in Brain Metastasis to Develop Novel Therapeutic Strategies$526,134
R01 · FY2025 · CA · contact PI
Exploring novel strategies for immunoprevention of estrogen receptor negative breast cancer$473,860
R01 · FY2025 · CA · contact PI
14 Functional Genomics Core$262,490
P30 · FY2025 · CA · contact PI
Exploring new strategy for breast cancer immunoprevention by targeting histamine receptor H1$189,338
R21 · FY2025 · CA
26 Cancer Biology and Metastasis$49,384
P30 · FY2025 · CA · contact PI
Exploring the Function of MHC-II/Lag3 Axis in Brain Metastasis to Develop Novel Therapeutic Strategies$499,828
R01 · FY2024 · CA · contact PI
Exploring novel strategies for immunoprevention of estrogen receptor negative breast cancer$450,168
R01 · FY2024 · CA · contact PI
14 Functional Genomics Core$246,847
P30 · FY2024 · CA · contact PI
Exploring new strategy for breast cancer immunoprevention by targeting histamine receptor H1$227,205
R21 · FY2024 · CA
26 Cancer Biology and Metastasis$46,441
P30 · FY2024 · CA · contact PI
Exploring the Function of MHC-II/Lag3 Axis in Brain Metastasis to Develop Novel Therapeutic Strategies$515,611
R01 · FY2023 · CA · contact PI
Exploring novel strategies for immunoprevention of estrogen receptor negative breast cancer$455,035
R01 · FY2023 · CA · contact PI
Combating Breast Cancer Brain Metastasis by Blocking the Two-Pronged Driver Kinase Function of CDK5$444,573
R01 · FY2023 · CA · contact PI
14 Functional Genomics Core$232,779
P30 · FY2023 · CA · contact PI
26 Cancer Biology and Metastasis$18,707
P30 · FY2023 · CA · contact PI
Exploring the Function of MHC-II/Lag3 Axis in Brain Metastasis to Develop Novel Therapeutic Strategies$526,134
R01 · FY2022 · CA · contact PI
Combating Breast Cancer Brain Metastasis by Blocking the Two-Pronged Driver Kinase Function of CDK5$444,573
R01 · FY2022 · CA · contact PI
14 Functional Genomics Core$232,779
P30 · FY2022 · CA · contact PI
26 Cancer Biology and Metastasis$18,707
P30 · FY2022 · CA · contact PI
Combating Breast Cancer Brain Metastasis by Blocking the Two-Pronged Driver Kinase Function of CDK5$453,646
R01 · FY2021 · CA · contact PI
Inhibition of brain metastasis by blocking MAPK12 driver kinase functions$432,573
R01 · FY2021 · CA · contact PI
14 Functional Genomics Core$232,779
P30 · FY2021 · CA · contact PI
26 Cancer Biology and Metastasis$18,707
P30 · FY2021 · CA · contact PI
Inhibition of brain metastasis by blocking MAPK12 driver kinase functions$552,495
R01 · FY2020 · CA · contact PI
Combating Breast Cancer Brain Metastasis by Blocking the Two-Pronged Driver Kinase Function of CDK5$453,646
R01 · FY2020 · CA · contact PI
14 Functional Genomics Core$232,381
P30 · FY2020 · CA · contact PI
26 Cancer Biology and Metastasis$18,675
P30 · FY2020 · CA · contact PI
Combating Breast Cancer Brain Metastasis by Blocking the Two-Pronged Driver Kinase Function of CDK5$453,646
R01 · FY2019 · CA · contact PI
Inhibition of brain metastasis by blocking MAPK12 driver kinase functions$419,594
R01 · FY2019 · CA · contact PI
Target p70S6K for Chemodietary Prevention/Early Intervention of ER- Breast Cancer$355,019
R01 · FY2019 · CA · contact PI
Co-targeting PDAC tumor cells and the microenvironment to succeed in EGFR/ErbB2-targeted therapy$168,779
R21 · FY2019 · CA · contact PI
Inhibition of brain metastasis by blocking MAPK12 driver kinase functions$116,146
R01 · FY2019 · CA · contact PI
Inhibition of brain metastasis by blocking MAPK12 driver kinase functions$432,573
R01 · FY2018 · CA · contact PI
Target p70S6K for Chemodietary Prevention/Early Intervention of ER- Breast Cancer$366,000
R01 · FY2018 · CA · contact PI
Co-targeting PDAC tumor cells and the microenvironment to succeed in EGFR/ErbB2-targeted therapy$208,800
R21 · FY2018 · CA · contact PI
Inhibition of brain metastasis by blocking MAPK12 driver kinase functions$432,573
R01 · FY2017 · CA · contact PI
Target p70S6K for Chemodietary Prevention/Early Intervention of ER- Breast Cancer$366,000
R01 · FY2017 · CA · contact PI
Stromal activation in the progression of high ErbB2/1433zeta DCIS to IBC$385,204
R01 · FY2016 · CA · contact PI
Target p70S6K for Chemodietary Prevention/Early Intervention of ER- Breast Cancer$366,000
R01 · FY2016 · CA · contact PI
Stromal activation in the progression of high ErbB2/1433zeta DCIS to IBC$385,204
R01 · FY2015 · CA · contact PI
Target p70S6K for Chemodietary Prevention/Early Intervention of ER- Breast Cancer$366,000
R01 · FY2015 · CA · contact PI
Stromal activation in the progression of high ErbB2/1433zeta DCIS to IBC$118,912
R01 · FY2015 · CA · contact PI
Stromal activation in the progression of high ErbB2/1433zeta DCIS to IBC$258,303
R01 · FY2014 · CA · contact PI
Metabolic Deregulation by 14-3-3 in Mammary Tumor Progression$165,315
P01 · FY2014 · CA · contact PI
Stromal activation in the progression of high ErbB2/1433zeta DCIS to IBC$250,315
R01 · FY2013 · CA · contact PI
Metabolic Deregulation by 14-3-3 in Mammary Tumor Progression$160,208
P01 · FY2013 · CA · contact PI
Stromal activation in the progression of high ErbB2/1433zeta DCIS to IBC$266,292
R01 · FY2012 · CA · contact PI
Metabolic Deregulation by 14-3-3 in Mammary Tumor Progression$170,431
P01 · FY2012 · CA · contact PI
Metabolic Deregulation by 14-3-3 in Mammary Tumor Progression$170,430
P01 · FY2011 · CA · contact PI
Metabolic Deregulation by 14-3-3 in Mammary Tumor Progression$175,703
P01 · FY2010 · CA · contact PI
PTEN Deficiency and Trastuzumab Resistance$269,341
P50 · FY2009 · CA · contact PI
14-3-3zeta in ErbB2 Mediated Mammary Carcinogenesis$254,494
R01 · FY2009 · CA · contact PI
14-3-3zeta in Early Stages of Breast Cancer Progression$264,158
R01 · FY2008 · CA · contact PI
14-3-3zeta in ErbB2 Mediated Mammary Carcinogenesis$254,494
R01 · FY2008 · CA · contact PI
PTEN Deficiency and Trastuzumab Resistance$181,323
P50 · FY2008 · CA · contact PI
14-3-3zeta in Early Stages of Breast Cancer Progression$264,158
R01 · FY2007 · CA · contact PI
14-3-3zeta in ErbB2 Mediated Mammary Carcinogenesis$254,494
R01 · FY2007 · CA · contact PI
14-3-3zeta in Early Stages of Breast Cancer Progression$272,048
R01 · FY2006 · CA · contact PI
14-3-3zeta in ErbB2 Mediated Mammary Carcinogenesis$262,095
R01 · FY2006 · CA · contact PI
14-3-3zeta in Early Stages of Breast Cancer Progression$278,595
R01 · FY2005 · CA
14-3-3zeta in ErbB2 Mediated Mammary Carcinogenesis$268,403
R01 · FY2005 · CA
14-3-3zeta in Early Stages of Breast Cancer Progression$278,595
R01 · FY2004 · CA
ERBB2 RECEPTOR SIGNALING AND BREAST CANCER METASTASIS$252,871
R01 · FY2002 · CA
ERBB2 RECEPTOR SIGNALING AND BREAST CANCER METASTASIS$245,508
R01 · FY2001 · CA
ERBB2 RECEPTOR SIGNALING AND BREAST CANCER METASTASIS$238,355
R01 · FY2000 · CA